By: Guillen H.B. No. 4160
A BILL TO BE ENTITLED
AN ACT
relating to the creation of the Alzheimer's Research Collaborative
of Texas.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. Subchapter D, Chapter 102, Health and Safety
Code, is amended by adding Section 102.157 to read as follows:
Sec. 102.157. OVERSIGHT COMMITTEE FOR NEURODEGENERATIVE
DISEASES. (a) In this section:
(1) "Committee" means the Oversight Committee for
Neurodegenerative Diseases.
(2) "Nationally designated" means a designation from
the National Institute on Aging.
(3) "Research collaborative" means the Alzheimer's
Research Collaborative of Texas.
(b) The Oversight Committee for Neurodegenerative Diseases
is the governing body of the Alzheimer's Research Collaborative of
Texas. The committee is composed of the following eight members:
(1) four members appointed by the lieutenant governor;
and
(2) four members appointed by the speaker of the house
of representatives.
(c) In making appointments to the committee, the lieutenant
governor and the speaker of the house of representatives must each
appoint:
(1) three members who are physicians or scientists
with extensive experience in the field of Alzheimer's disease and
neurology; and
(2) one member of the public.
(d) From each group of appointees under Subsection (c)(1),
one appointee must represent a nationally designated Alzheimer's
Disease Research Center and shall serve as co-chair of the
committee.
(e) A member of the committee serves at the will of the
official who appointed the member.
(f) The research collaborative is established to support
Alzheimer's disease research described by Subsection (h). The
committee shall oversee the review processes and related procedures
of the collaborative.
(g) The committee shall establish standards and hire
personnel as necessary to ensure the proper use of funds authorized
for Alzheimer's disease research, facilities development, and
caregiver resources consistent with the powers and duties described
under Section 102.051.
(h) The committee shall establish criteria for the research
collaborative to support institutions of learning and advanced
medical research facilities and collaborations in this state in all
stages of finding the causes of Alzheimer's disease and other
neurodegenerative diseases in humans and developing cures, from
laboratory research to clinical trials, including programs to
address the problem of access to advanced treatment for Alzheimer's
disease.
(i) The committee shall establish criteria for prioritizing
its review of applications for grants to:
(1) academic medical centers;
(2) medical research facilities; and
(3) collaborations with a nationally designated
Alzheimer's Disease Research Center.
SECTION 2. This Act takes effect September 1, 2023.